All Insights
CMA's FinTech focus continues
Crowdfunding platforms merger is abandoned following the Competition and Markets Authority's (CMA) adverse provisional findings.
Quoted Company Update | March 2021
Welcome to the latest edition of Osborne Clarke's Quoted Company Update.
UK Listings Review | What do you need to know?
Wide sweeping reforms have been proposed by the UK Listings Review, chaired by Lord Jonathan Hill, as part of a
UK National Security and Investment Bill | Fewer tech transactions to be caught under revised scope of rules
The government has revised the planned scope of new controls on investment into certain UK industries.
Event note | Workforce Solutions sector M&A - what's happening in current deals in the US and UK?
On 9 March Osborne Clarke hosted, in association with Paul Pincus of New York law firm Ortoli Rosenstadt, a webinar
Cryptoassets case law homes in on location, location, location!
Slowly but surely the English courts are defining the legal status of cryptocurrencies by confirming the rights that go with
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 4)
Good practices recommended by the Belgian Financial Services and Markets Authority (FSMA)
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information
What are the best practices for biotech companies in relation to inside information and the Belgian Financial Services and Markets
Considerations and best practices for Belgian listed biotech companies when assessing and disclosing inside information (Part 2)
How does the Belgian Financial Services and Markets Authority (FSMA) determine what qualifies as inside information for biotech companies?
Shareholder meetings: is it time for a change?
Following the adoption of virtual and hybrid meetings during the global pandemic, the GC100 has released a discussion paper around
